Monsenso has entered a new million-kroner agreement with a global pharmaceutical company and hereby expands its activities to six countries in the Middle East. As part of the agreement, Monsenso will provide its solution for patient monitoring and treatment support in the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar and Bahrain. Monsenso's clinically validated solution will be used to support the treatment of depression and schizophrenia. Patients are provided with an app, which is used to collect real-time patient-reported information and to give patients access to information about their disorder between consultations. Clinicians gain access to a clinical web portal and can follow their patients remotely and gain valuable information about behavior, medication intake and symptoms. This enables clinicians to provide a data-driven treatment and allow for proactive follow-up. In addition, the solution supports communication between patients and therapists.